Avenda Health

Avenda Health

Precision Medicine & Genomics

About Avenda Health

Avenda Health is a precision medicine company focused on transforming prostate cancer care through artificial intelligence. The company's flagship product, Unfold AI, is an FDA-cleared platform that generates detailed 3D Cancer Estimation Maps (CEMs) to visualize the precise location and extent of prostate cancer within the prostate gland. By analyzing standard-of-care patient data including MRI scans, fusion biopsy results, pathology reports, and PSA levels, Unfold AI significantly outperforms traditional MRI in identifying where cancer resides. Clinical studies demonstrate that physicians using Unfold AI achieve 84% accuracy in identifying cancer extent, and patients treated with Unfold AI margins are 71% more likely to be cancer-free. The platform addresses a critical gap in prostate cancer treatment: without precise cancer mapping, whole-gland treatments lead to urinary and sexual dysfunction in over 50% of patients, while focal therapy without AI guidance leaves 24-49% of patients with residual cancer. Unfold AI supports multiple treatment modalities including active surveillance, prostatectomy, focal therapy, and radiotherapy by providing actionable insights for surgical planning, biopsy guidance, and treatment targeting. The technology is based on over 100,000 patient data points gathered over 10 years of research and validated in multiple peer-reviewed clinical studies. Avenda Health serves urologists, radiation oncologists, and healthcare systems across the United States, working to make precision-guided prostate cancer care accessible to patients nationwide.

Mission & Story

Mission

Patients should not have to choose between treating their prostate cancer and maintaining their quality of life

Founding Story

Co-founded by CEO Shyam Natarajan, PhD, who has been featured in interviews discussing the company's mission to redefine prostate cancer care

Clinical Focus

Medical conditions and clinical areas addressed by Avenda Health.

Prostate cancer (Gleason Grade 2 or greater)Localized prostate cancer requiring treatment planning

Who It Serves

UrologistsRadiation oncologistsUrology practicesHealthcare systems

Milestones & Awards

Recent Milestones

CMS established national payment for Unfold AI (July 2024); Partnership with EDAP for world's first AI-assisted Focal One® Robotic HIFU procedures (September 2024); Won Top Digital Health Award at HLTH conference (October 2025); Multiple clinical study publications in 2024-2025

Awards & Recognition

Top Digital Health Award at HLTH 2025; CMS national payment establishment (July 2024)

Key Partnerships

EDAP (Focal One® Robotic HIFU partnership)Kasraeian UrologyMultiple urology practices across Southeast US

Social & Media

Follow on

Company Details

Work here?

Claim this listing to update company information and connect with our audience.

Claim This Listing

Security & Compliance

FDA 510(k) clearance
Last updated Jun 28, 2026

Similar Companies in this Market

View all 60
23andMe

23andMe

23andMe uses AI to analyze genetic data and provide personalized health summaries, risk assessments, and wellness recommendations based on genomic insights.

2bPrecise

2bPrecise

AI-powered precision medicine platform for personalized treatment recommendations and genomic analysis.

ACT Genomics

ACT Genomics

AI-powered genomic analysis platform for precision medicine and personalized treatment recommendations.

Adaptive Biotechnologies

Adaptive Biotechnologies

Adaptive Biotechnologies uses AI and machine learning to decode the immune system and identify disease-specific immune signatures for diagnosis and personalized treatment.

Ambry Genetics

Ambry Genetics

Ambry Genetics is a leading clinical genetic testing laboratory specializing in hereditary cancer, rare disease, cardiology, and neurology testing. The company provides advanced genetic testing solutions with paired DNA/RNA analysis and comprehensive patient support programs.

Ataraxis

Ataraxis

Ataraxis develops AI-native precision medicine tools that predict patient outcomes and treatment response in oncology. Their flagship product, Ataraxis Breast, provides clinically validated prognostic and predictive tests for breast cancer using multi-modal AI analysis of pathology images and clinical data.

Base Genomics

Base Genomics

Base Genomics appears to be a company in the Precision Medicine & Genomics space, but the scraped website content is empty or inaccessible, preventing detailed analysis of their offerings and target market.

Beacon Biosignals

Beacon Biosignals

Beacon Biosignals is a precision neuroscience platform that uses AI-powered technology to accelerate drug development and power home sleep testing diagnostics. The company collects, integrates, and analyzes EEG data across the full drug development lifecycle.

Data Accuracy Notice: Company information on HealthAI Central is compiled from public sources and updated regularly. While we strive for accuracy, details such as funding figures, employee counts, and product offerings may change. We recommend verifying critical information directly with the company before making business decisions.